Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years - Kowdley, K V; Bowlus, C L; Levy, C; Akarca, U; Alvares-da-Silva, M R; Andreone, P; Arrese, M; Corpechot, C; Elbeshbeshy, H; Francque, S; Heneghan, M A; Invernizzi, P; Jacobson, I M; Jones, D; Kruger, F C; Lawitz, E; Mayo, M J; Shiffman, M L; Sonderup, M; Swain, M G; Valera, J M; Vargas, V; Vierling, J M; Villamil, A; Raskino, C; Antunes, N; Sleiman, M; Cranham, V; Miller, B; Schattenberg, J M (Zeitschrift für Gastroenterologie, 2025)